US equities
|
NVDA
$234.63
▲+1.63%
MU
$1,077.31
▼-1.83%
SPCX
$158.55
▲+7.08%
TSLA
$371.65
▲+4.95%
SNDK
$1,722.67
▼-3.64%
STX
$837.44
▼-11.44%
AMD
$631.15
▲+2.50%
INTC
$120.03
▲+0.03%
NVDA
$234.63
▲+1.63%
MU
$1,077.31
▼-1.83%
SPCX
$158.55
▲+7.08%
TSLA
$371.65
▲+4.95%
SNDK
$1,722.67
▼-3.64%
STX
$837.44
▼-11.44%
AMD
$631.15
▲+2.50%
INTC
$120.03
▲+0.03%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Bayer
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
September 09, 2024
From
Bayer
Via
Business Wire
Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024
September 05, 2024
From
Bayer
Via
Business Wire
Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause
September 04, 2024
From
Bayer
Via
Business Wire
ESC 2024: Late-Breaking KERENDIA® (finerenone) Investigational Data Presented
September 01, 2024
From
Bayer
Via
Business Wire
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
August 29, 2024
From
Bayer
Via
Business Wire
Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)
August 29, 2024
From
Bayer
Via
Business Wire
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
August 28, 2024
From
Bayer
Via
Business Wire
Fast, Stable, Secure: New Bayer Hardware Simplifies Farm Activities, Equipment Setup and Provides Increased Value to Farmers
August 26, 2024
From
Bayer
Via
Business Wire
The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data
August 22, 2024
From
Bayer
Via
Business Wire
Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease
August 22, 2024
From
Bayer
Via
Business Wire
Bayer and Alara Imaging Announce Collaboration
August 05, 2024
From
Bayer
Via
Business Wire
Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA® (finerenone) in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
August 05, 2024
From
Bayer
Via
Business Wire
Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
August 01, 2024
From
Bayer
Via
Business Wire
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)
July 17, 2024
From
Bayer
Via
Business Wire
Bayer and Kroger Team Up with Luke Bryan and Feeding America to Improve Access to Nutritious Food
July 13, 2024
From
Bayer
Via
Business Wire
One A Day® Launches Science-Backed Cellular Aging Support Supplement
July 09, 2024
From
Bayer
Via
Business Wire
Bayer and Rad AI Announce Collaboration agreement
June 27, 2024
From
Bayer
Via
Business Wire
Reality TV Couple Lauren Speed-Hamilton and Cameron Hamilton Help Daters Keep the FIZZ Alive with NEW Alka-Seltzer® Fizzy Melts
June 18, 2024
From
Bayer
Via
Business Wire
44 Members of Congress Call for Federal Screening Recommendations for Kidney Disease
June 05, 2024
From
Bayer
Via
Business Wire
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
May 16, 2024
From
Bayer
Via
Business Wire
Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting
May 16, 2024
From
Bayer
Via
Business Wire
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
May 15, 2024
From
Bayer
Via
Business Wire
Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress
May 13, 2024
From
Bayer
Via
Business Wire
One A Day® Partners with Julian Edelman to Share #WellnessConfessionals
May 13, 2024
From
Bayer
Via
Business Wire
Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress
May 10, 2024
From
Bayer
Via
Business Wire
WomenHeart and Bayer Join Forces to Enhance Heart Health Awareness and Education Among Women Across the U.S.
May 10, 2024
From
Bayer
Via
Business Wire
Midol® Addresses Period Education and Normalization of Menstrual Discomfort with PeriodTalk Initiative in Partnership with Nonprofit PERIOD.
May 09, 2024
From
Bayer
Via
Business Wire
Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause
May 08, 2024
From
Bayer
Via
Business Wire
Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues
April 24, 2024
From
Bayer
Via
Business Wire
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
April 11, 2024
From
Bayer
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
